

NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, CANADA, JAPAN, HONG KONG, SINGAPORE, SOUTH AFRICA, SWITZERLAND OR THE UNITED STATES OR IN ANY JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL.

PRESS RELEASE

Stockholm 27 April 2011



Board of Directors sets terms for rights issue

- Shareholders in Swedish Orphan Biovitrum AB (“Sobi” or the “Company”) as of the record date 5 May 2011 have preferential rights to subscribe for one new common share for every four shares held
- The subscription price is SEK 12 per share, which represents total rights issue proceeds of approximately SEK 637 million
- First day of trading in the Sobi share, excluding subscription right, will be 3 May 2011. The subscription period runs from and including 11 May 2011, up to and including 26 May 2011
- The rights issue is fully covered by subscription undertakings by major shareholders in Sobi and underwriting undertakings by Carnegie Investment Bank and Svenska Handelsbanken
- The rights issue is subject to approval by the Annual General Meeting, which will be held on 28 April 2011

The Board of Directors has now determined the terms, including the subscription price, for the rights issue that was decided on 28 March 2011. The rights issue is subject to approval by the Annual General Meeting, which will be held on Thursday 28 April 2011. For every share held in Sobi on the record date 5 May 2011, the holder is entitled to one subscription right. Four subscription rights entitle the holder to subscribe for one new common share in Sobi. The subscription price is SEK 12 per share which implies that the rights issue, if fully subscribed, will raise approximately SEK 637 million for Sobi, before transaction costs. No more than 53,045,319 new common shares may be issued, whereby the share capital may be increased by not more than approximately SEK 29,105,800.

First day of trading in the Sobi share, excluding subscription right, will be 3 May 2011. The record date at the Swedish Central Securities Depository, Euroclear Sweden AB, for participation in the rights issue is 5 May 2011. The subscription period will run from and including 11 May 2011, up to and including 26 May 2011, or such later date as decided by the Board of Directors. Subscription rights not exercised during the subscription period will be void and have no value. Subscription rights will be tradable on NASDAQ OMX Stockholm from and including 11 May 2011 up to and including 23 May 2011.

Allotment of shares subscribed for without the exercise of subscription rights, will firstly be allotted to those that also have subscribed for shares by exercising of subscription rights (in case of oversubscription, in proportion to the number of subscription rights used for subscription of shares), secondly, to others that have applied for subscription of shares without exercising subscription rights (in case of oversubscription, in proportion to the number of shares that each has applied to subscribe for without exercising subscription rights), and thirdly to the guarantors in proportion to their respective underwriting commitments.

Indicative timetable for the rights issue

28 April 2011	Annual General Meeting of shareholders to decide on the rights issue resolved by the Board of Directors
3 May 2011	First day of trading in the Sobi share, excluding subscription right

NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, CANADA, JAPAN, HONG KONG, SINGAPORE, SOUTH AFRICA, SWITZERLAND OR THE UNITED STATES OR IN ANY JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL.

5 May 2011	Estimated date of publication of the prospectus
5 May 2011	Record date for participation in the rights issue, i.e. shareholders registered in the share register of Sobi as of this date will receive subscription rights for participation in the rights issue
11 May–23 May 2011	Trading in subscription rights
11 May–26 May 2011	Subscription period
On or about 1 June 2011	Announcement of preliminary outcome

Commitments and underwriting

The shareholders Investor AB and Bo Jesper Hansen (the Chairman of the Board of Directors) have undertaken to subscribe for their respective pro rata shares of the rights issue, corresponding to approximately 44 per cent of the rights issue.

The remainder of the rights issue, corresponding to approximately 56 per cent is, subject to customary terms and conditions, underwritten by Carnegie Investment Bank and Svenska Handelsbanken. In addition, CEO Kennet Rooth also intends to subscribe for his pro rata share.

Financial and legal advisors

Carnegie Investment Bank and Handelsbanken Capital Markets are Joint Lead Managers and Joint Bookrunners in the rights issue. Mannheimer Swartling is acting as legal advisor to Sobi, and Linklaters is acting as legal advisor to the Joint Lead Managers.

For additional information, please contact

Kennet Rooth, CEO

Telephone: +46 8-697 20 00

The above information has been made public in accordance with the Swedish Securities Market Act and/or the Financial Instruments Trading Act. The information was released for public distribution on 27 April 2011 at 8.30 a.m. CET.

NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, CANADA, JAPAN, HONG KONG, SINGAPORE, SOUTH AFRICA, SWITZERLAND OR THE UNITED STATES OR IN ANY JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL.

IMPORTANT INFORMATION

The information in this press release is not intended for distribution, publication or public release, directly or indirectly, in or into Australia, Canada, Hong Kong, Japan, Singapore, South Africa, Switzerland, the United States or any other jurisdiction where the distribution of this press release may be unlawful. The distribution of this announcement may be restricted by law in certain jurisdictions and persons into whose possession any document or other information referred to herein comes should inform themselves about and observe any such restriction.

The information in this press release is not an offer to sell or a solicitation to buy shares. This press release is not a prospectus under the Prospectus Directive 2003/71/EC. A prospectus will be prepared and published in accordance with the Prospectus Directive and will thereafter be made available by the Company. Investors shall not subscribe for securities referred to in this press release other than on the basis of the information which will be included in such prospectus.

The information in this press release does not constitute or form a part of any offer or solicitation to purchase or subscribe for securities in the United States. The securities mentioned herein have not been, and will not be, registered under the United States Securities Act of 1933 (the "Securities Act") or under the securities laws of any state or other jurisdiction in the United States, and may not be offered or sold in the United States, except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act. There will be no public offer of securities in the United States.

The information in this press release may not be forwarded or distributed to any other person and may not be reproduced in any manner whatsoever. Any forwarding, distribution, reproduction, or disclosure of this information in whole or in part may be prohibited. Failure to comply with these instructions may result in a violation of the Securities Act or the applicable laws of other jurisdictions.

This press release may contain forward-looking statements. Words such as "expect", "believe", "estimate", "plan" and "forecast" in this press release are intended to indicate forward-looking statements. These forward looking statements reflect the current expectations on future events of the management at the time such statements are made, but are made subject to risks and uncertainties. All these forward-looking statements are based on the expectations and assumptions of the management and are deemed reasonable but uncertain and difficult to predict. Actual outcomes and results may differ significantly from the forward looking statements. The Company does not intend, nor undertakes, to update any such forward looking statements.